The Administrative Council for economic Defense (Cade) approved the establishment of joint venture between AstraZeneca and Fujifilm to develop and market the pharmaceutical product named FKB238, for use in the treatment of cancer.
The decision is published in the Diário Oficial da União (GIVE).
According to the companies, the FKB238 is a Biosimilar to Avastin, the competitor Roche. The operation is also under antitrust bodies analysis of Austria, China, Germany, South Korea and Taiwan.
Exame
News Item translated automatically
Click HERE to see original
